AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

871.383

-2.961-0.34%

Number of Gainers:11

Number of Losers:20

Number of Flat:15

PE:- -

High:875.874

Open:874.231

Low:865.875

Close:874.344

Loading ...

Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal

MT Newswires Live

Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why

BRIEF-Respiri Enters Partnership With Evolent Care Partners

BUZZ-Australia's Respri falls on discounted placement

Respiri Ltd-Proposed Issue of Securities - Rsh

THOMSON REUTERS

Respiri - All Currencies in AUD

THOMSON REUTERS

Respiri Ltd-Respiri Raises $4M Through Placement & Proposed Name Change

THOMSON REUTERS

Respiri Ltd - Enters Partnership With Evolent Care Partners' to Deliver Care Management Services in Hawaii

THOMSON REUTERS

Arcadium Lithium to be Delisted From ASX 200 Index

MT Newswires Live

5 high-quality ASX ETFs to buy in March

Monash IVF Group (ASX:MVF) Is Increasing Its Dividend To A$0.026

Simply Wall St.

When Will Imricor Medical Systems, Inc. (ASX:IMR) Breakeven?

Simply Wall St.

Press Release: Opthea Reports Half Year Results and Business Updates

BRIEF-Genetic Technologies's Creditors Resolve To Execute Benelong DOCA

BRIEF-Cann Group Posts HY Loss From Ordinary Activities After Tax A$10.7 Million

Cann Group Agrees to Drawdown on Convertible Loan Facility

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":871.38275,"timestamp":1741150799920,"preClose":874.3437,"halted":0,"volume":84743621,"delay":0,"changeRate":-0.003386,"change":-2.960938,"amount":159990404,"amplitude":0.011436,"prevYearClose":936.801,"fiveDayClose":877.613,"twentyDayClose":903.442,"turnoverRate":0.002284,"marketCap":140005610704.5,"floatMarketCap":136533699849.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":875.8735,"amplitude":0.011436,"preClose":874.3437,"low":865.87463,"latestPrice":871.38275,"volume":84743621,"delay":0,"open":874.2309,"prevYearClose":936.801,"prevWeekClose":863.841,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":877.613,"twentyDayClose":903.442,"sixtyDayClose":934.137,"secType":"PLATE","market":"AU","turnoverRate":0.002284,"marketCap":140005610704.5,"floatMarketCap":136533699849.75,"timestamp":1741150799920,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":11,"down":20,"flat":15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516364524","title":"Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364524?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:43","pubTimestamp":1740966234,"startTime":"0","endTime":"0","summary":"Opthea  announced the publication of data from a phase 2b trial of its sozinibercept drug candidate for wet age-related macular degeneration in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina, according to a Monday Australian bourse filing.The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-nave patients.The randomized, controlled trial saw sozinibercept combination therapy leading to superior visual gains compared to therapy with only ranibizumab at 24 weeks.Analysis of the data showed that in patients with occult and minimally classic lesions, representing 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a \"statistically significant\" gain in best corrected visual acuity compared to ranibizumab alone.Opthea's shares rose almost 3% in recent trading on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","BK7508","OPT","BK7067"],"gpt_icon":0},{"id":"2516574632","title":"Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why","url":"https://stock-news.laohu8.com/highlight/detail?id=2516574632","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516574632?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:10","pubTimestamp":1740964200,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd  share price is racing higher today. Again. Shares in the  S&P/ASX 300 Index  clinical-stage biotechnology company closed on Friday trading for $2.52. In earlier trade, shares were up 8.3% at $2.73 each. That saw the stock up an eye-popping 810% since this time last year. Or enough to turn an $8,000 investment into $72,800. In just 12 months. After some likely profit-taking, the Mesoblast share price is currently trading at $2.65, up 5.2%.  Here's what's grabbing ASX 200 investor interest today. Mesoblast share price benefits from its own success The ASX 200 biotech stock appears to be garnering additional tailwinds today generated by its own lengthy run higher. You see, with the Mesoblast share price having roared from 30 cents a share 12 months ago to $2.65 today, the company's market cap has surged to $3.4 billion. Why is that important?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/up-810-in-a-year-the-mesoblast-share-price-is-surging-again-on-monday-heres-why/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LTM.AU","MSB.AU","A200.AU","BK7508","BK7507","MESO","BK7501","BK7067","BK7511","BK7095","BK4139","RIO.AU","BK7036","IOZ.AU","XKO.AU"],"gpt_icon":0},{"id":"2516752965","title":"BRIEF-Respiri Enters Partnership With Evolent Care Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752965?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:04","pubTimestamp":1740963897,"startTime":"0","endTime":"0","summary":"BRIEF-Respiri Enters Partnership With Evolent Care PartnersMarch 3 (Reuters) - Respiri Ltd RSH.AX:ENTERS PARTNERSHIP WITH EVOLENT CARE PARTNERS' TO DELIVER CARE MANAGEMENT SERVICES IN HAWAIIFurther company coverage: RSH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PL008:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK7508","RSH.AU","BK7007"],"gpt_icon":0},{"id":"2516252565","title":"BUZZ-Australia's Respri falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516252565","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516252565?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:20","pubTimestamp":1740961253,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Respri falls on discounted placement** Shares of Australia's Respiri Ltd RSH.AX fall as much as 8.3% to A$0.044, on track to record their second straight session of losses** Stock at its lowest level since February 25** e-health software services provider announces A$4 million   placement at an issue price of A$0.04 per share** Issue price at a discount of 16.7% to stock's last closing** Funds from placement to help \"support investments in the business to execute on recent and expected customer wins\" - RSH** Stock down 47% this year so far  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM007:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","BK7508","BK7503","RSH.AU"],"gpt_icon":0},{"id":"2516540429","title":"Respiri Ltd-Proposed Issue of Securities - Rsh","url":"https://stock-news.laohu8.com/highlight/detail?id=2516540429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516540429?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:44","pubTimestamp":1740955465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nTUEBC0LHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7007","RSH.AU","BK7503"],"gpt_icon":0},{"id":"2516554042","title":"Respiri - All Currencies in  AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2516554042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516554042?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:43","pubTimestamp":1740955411,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nTUEWCBLK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","BK7508","RSH.AU","BK7503"],"gpt_icon":0},{"id":"2516540179","title":"Respiri Ltd-Respiri Raises $4M Through Placement & Proposed Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2516540179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516540179?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:43","pubTimestamp":1740955411,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nTUEWCBLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7503","RSH.AU","BK7007"],"gpt_icon":0},{"id":"2516540553","title":"Respiri Ltd -  Enters Partnership With Evolent Care Partners' to Deliver Care Management Services in Hawaii","url":"https://stock-news.laohu8.com/highlight/detail?id=2516540553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516540553?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:27","pubTimestamp":1740954422,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nFWN3PL008:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RSH.AU","BK7508","BK7503","BK7007"],"gpt_icon":0},{"id":"2516846547","title":"Arcadium Lithium to be Delisted From ASX 200 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2516846547","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516846547?lang=en_us&edition=fundamental","pubTime":"2025-03-03 05:31","pubTimestamp":1740951065,"startTime":"0","endTime":"0","summary":"Arcadium Lithium  will be removed from the S&P/ASX 200 index as the company will be acquired by Rio Tinto , according to a Friday Australian bourse filing.S&P Dow Jones Indices will remove Arcadium Lithium from the S&P/ASX 200 before the opening of trading on March 6 and replace it with Mesoblast , the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLS.AU","BK7508","RIO.AU","BK7067","BK7511","ALTM","BK4144","BK7507","LTM.AU","BK7095","BK7501","MSB.AU","BK7036","BK4109"],"gpt_icon":0},{"id":"2516154781","title":"5 high-quality ASX ETFs to buy in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2516154781","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516154781?lang=en_us&edition=fundamental","pubTime":"2025-03-03 04:24","pubTimestamp":1740947084,"startTime":"0","endTime":"0","summary":"For investors looking to diversify their portfolios and gain exposure to strong-performing sectors or indices, exchange-traded funds (ETFs) can be a great way to do it. That's because ASX ETFs offer a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/5-high-quality-asx-etfs-to-buy-in-march/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4581","IVV","BK7508","ATEC.AU","BK4559","CBA.AU","SSO","BK4585",".SPX","BK4550","OEF","SH","XJO.AU","XAO.AU","FDN","BK7507","ASIA.AU","BK7511","SDS","CSL.AU","BK4534","OEX","UPRO","SPXU","BHP.AU","VOO","WTC.AU","BK7067","BK4588","VAS.AU","BK4504","BK7135","BK7503","MOAT.AU","BK7095","XKO.AU","XRO.AU","ESmain","BK7016","SPY","IVV.AU","BK7501"],"gpt_icon":0},{"id":"2516620225","title":"Monash IVF Group (ASX:MVF) Is Increasing Its Dividend To A$0.026","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620225","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620225?lang=en_us&edition=fundamental","pubTime":"2025-03-02 07:17","pubTimestamp":1740871079,"startTime":"0","endTime":"0","summary":"Monash IVF Group Limited  will increase its dividend on the 11th of April to A$0.026, which is 4.0% higher than last year's payment from the same period of A$0.025. This will take the annual payment to 4.1% of the stock price, which is above what most companies in the industry pay.Check out our latest analysis for Monash IVF Group. Monash IVF Group Might Find It Hard To Continue The Dividend. Impressive dividend yields are good, but this doesn't matter much if the payments can't be sustained. While Monash IVF Group is not profitable, it is paying out less than 75% of its free cash flow, which means that there is plenty left over for reinvestment into the business. In general, cash flows are more important than the more traditional measures of profit so we feel pretty comfortable with the dividend at this level.Over the next year, EPS is forecast to rise by 15.7%. While it is good to see income moving in the right direction, it still looks like the company won't achieve profitability. H","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monash-ivf-group-asx-mvf-231759766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4588","MVF.AU","VFC","BK7508","LU1670710588.SGD","LU1670711123.USD","LU1670711040.USD","LU1670710661.SGD","BK4504","BK4202","BK7113","MVF","BK4585"],"gpt_icon":0},{"id":"2516344307","title":"When Will Imricor Medical Systems, Inc. (ASX:IMR) Breakeven?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516344307","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516344307?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:44","pubTimestamp":1740779079,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Imricor Medical Systems, Inc.'s  business as it appears the company may be on the cusp of a considerable accomplishment. Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging  compatible products for cardiac catheter ablation procedures in the United States. The AU$427m market-cap company posted a loss in its most recent financial year of US$23m and a latest trailing-twelve-month loss of US$20m shrinking the gap between loss and breakeven. The most pressing concern for investors is Imricor Medical Systems' path to profitability – when will it breakeven?Below we will provide a high-level summary of the industry analysts’ expectations for the company.View our latest analysis for Imricor Medical Systems. According to some industry analysts covering Imricor Medical Systems, breakeven is near. They anticipate the company to incur a final loss in 2026, before generating po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imricor-medical-systems-inc-asx-214439083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","MRI.AU","BK7508","IMR.AU","BK7057","BK7503"],"gpt_icon":0},{"id":"2514585323","title":"Press Release: Opthea Reports Half Year Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585323","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514585323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents of $131.9M as of December 31, 2024. Cash runway extends through anticipated topline data readouts of COAST  and ShORe . \"Opthea is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live fuller and healthier lives,\" said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. \"Sozinibercept has the potential to be the first product in nearly 20 years to demonstrate superior visual outcomes in combination with standard of care therapy, and we look forward to the anticipated topline data readouts of our two Phase 3 clinical trials in early Q2 and mid-calendar year 2025.\". Tom Reilly, Chief Financial Officer of Opthea, added: \"Looking ahead, we expect our cash and cash equivalents to fund the Company through the anticipated topline data readouts of the Phase 3 COAST and ShORe trials. In addition, we continue to progress our manufacturing  activities as we prepare our Biologics License Application  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","BK7508","LU1303367103.USD","BK4532","LU2458330243.SGD","BK4585","LU2098885051.SGD","BK4006","LU1803068979.SGD","LU0823421416.USD","IE0009356076.USD","LU2360106780.USD","BK4573","BK4141","IE00BHPRN162.USD","OPT.AU","LU0642271901.SGD","LU1923623000.USD","GFS","LU1316542783.SGD","LU0979878070.USD","LU1989764664.SGD","LU2250418816.HKD","LU2458330169.SGD","LU0056508442.USD","IE00BMPRXN33.USD","LU0823421333.USD","LU0823434583.USD","LU1880398471.USD","BK4529","BK4575","BK4543","LU0149725797.USD","IE00BKVL7J92.USD","IE00B5949003.HKD","BK7067","IE00BMPRXR70.SGD","LU0719512351.SGD","LU0390134368.USD","LU1852331112.SGD","LU0127658192.USD","LU1951198990.SGD","LU0971096721.USD","CMC","OPT","BK4139","LU1951200564.SGD","LU0889565833.HKD","BK4566"],"gpt_icon":1},{"id":"2514314534","title":"BRIEF-Genetic Technologies's Creditors Resolve To Execute Benelong DOCA","url":"https://stock-news.laohu8.com/highlight/detail?id=2514314534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514314534?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:15","pubTimestamp":1740730533,"startTime":"0","endTime":"0","summary":"BRIEF-Genetic Technologies's Creditors Resolve To Execute Benelong DOCAFeb 28 (Reuters) - Genetic Technologies Ltd GTG.AX:CREDITORS RESOLVE TO EXECUTE BENELONG DOCAFurther company coverage: GTG.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","GTG.AU","BK7508"],"gpt_icon":0},{"id":"2514313487","title":"BRIEF-Cann Group Posts HY Loss From Ordinary Activities After Tax A$10.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313487?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:25","pubTimestamp":1740727549,"startTime":"0","endTime":"0","summary":"BRIEF-Cann Group Posts HY Loss From Ordinary Activities After Tax A$10.7 MillionFeb 28 (Reuters) - Cann Group Ltd CAN.AX:HY LOSS FROM ORDINARY ACTIVITIES AFTER TAX A$10.7 MILLIONHY REVENUES FROM ORDINARY ACTIVITIES A$6.5 MILLIONFurther company coverage: CAN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAN.AU","BK7502","BK7508","BK7096"],"gpt_icon":0},{"id":"2514213392","title":"Cann Group Agrees to Drawdown on Convertible Loan Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2514213392","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514213392?lang=en_us&edition=fundamental","pubTime":"2025-02-28 14:20","pubTimestamp":1740723617,"startTime":"0","endTime":"0","summary":"Cann Group  said it agreed to a AU$750,000 drawdown on its convertible note facility with Obsidian Global on Thursday, according to a Friday Australian bourse filing.The facility agreement was amended to enable the drawdown to occur in two stages.In the first stage, AU$150,000 will be drawn down, while AU$600,000 for the second stage will be received following the filing of an applicable prospectus.The firm's shares fell over 1% on market close on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","CAN.AU","BK7502"],"gpt_icon":0}],"pageSize":16,"totalPage":9,"pageCount":3,"totalSize":142}]}}